Finance

Lists
Why is TXG up ४.१९%?
Dive Deeper
TXG:NASDAQ
10X Genomics Inc
US$ ९७.४२
+४.१९%
(+३.९२) 1D
अक्टोबर ५, १५:३२:१० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TXG...
Open
US$ ९३.५०
High
US$ ९७.६५
Low
US$ ९२.२६
Mkt. cap
१२.६६ अरब
Avg. vol.
२९.९५ लाख
Volume
१७.१३ लाख
52-wk high
US$ ९७.६५
52-wk low
US$ ११.१६
EPS
-US$ ०.५९
Beta
१.९९
Shares outstanding
१२.०२ करोड
No. of employees
१ हजार
Open
US$ ९३.५०
High
US$ ९७.६५
Low
US$ ९२.२६
Mkt. cap
१२.६६ अरब
Avg. vol.
२९.९५ लाख
Volume
१७.१३ लाख
52-wk high
US$ ९७.६५
52-wk low
US$ ११.१६
EPS
-US$ ०.५९
Beta
१.९९
Shares outstanding
१२.०२ करोड
No. of employees
१ हजार
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
३ घण्टा पहिले
10x Genomics stock hits 52-week high at 95.22 USD By Investing.com
Stock Traders Daily
Stock Traders Daily
·
१ दिन पहिले
How 10x Genomics Inc. (TXG) Affects Rotational Strategy Timing
Profile
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. Wikipedia
About 10X Genomics Inc
CEOSerge Saxonov
Employees१.१८ हजार
Founded२०१२
HeadquartersPleasanton, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to TXG in the past 3 months
Buy
Buy
7
Hold
9
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TXG in the last 3 months.
Highest
Current US$ ९७.४२
US$ ११०.०० (+१२.९१%)
Average
US$ ६३.२१ (-३५.१२%)
Lowest
US$ ४०.०० (-५८.९४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matt Larew
William Blair
Buy
Maintained
-
-
09/29/2026
Puneet Souda
Leerink Partners
Hold
Maintained
US$ ९०.००
-७.६%
09/29/2026
David Westenberg
Piper Sandler
Hold
Reiterated
US$ ८०.००
-१७.९%
09/28/2026
Unknown Analyst
Argus Research
Buy
Initiated
US$ ११०.००
+१२.९%
09/28/2026
John Eade
Argus Research
Buy
Initiated
US$ ११०.००
+१२.९%
09/25/2026
Unknown Analyst
UBS
Hold
Initiated
US$ ६८.००
-३०.२%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
US$ ६८.००
-३०.२%
09/09/2026
Dan Leonard
RBC Capital
Hold
Initiated
US$ ७०.००
-२८.१%
09/01/2026
Unknown Analyst
Stephens
Buy
Reiterated
US$ ६५.००
-३३.३%
08/12/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
US$ ५०.००
-४८.७%
08/10/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
US$ ५०.००
-४८.७%
08/11/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
US$ ६०.००
-३८.४%
08/10/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Reiterated
US$ ४०.००
-५८.९%
08/10/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
08/07/2026
Tycho Peterson
Jefferies
Buy
Reiterated
US$ ५३.००
-४५.६%
08/07/2026
Patrick B Donnelly
Citi
Hold
Maintained
US$ ५०.००
-४८.७%
08/07/2026
‏Brendan Digan‏
Citi
Hold
Maintained
US$ ५०.००
-४८.७%
08/07/2026
Luke Sergott
Barclays
Buy
Maintained
US$ ५२.००
-४६.६%
08/06/2026
Daniel Brennan
TD Cowen
Hold
Maintained
US$ ४७.००
-५१.८%
07/15/2026
Justin Bowers
Deutsche Bank
Hold
Maintained
US$ २३.००
-७६.४%
05/08/2026
Last report
२०२६ अगस्ट ६
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ ०.०३ / -US$ ०.०२
+२५८.३७%beat
Revenue / Est. (USD)
१५.१० करोड / १४.६६ करोड
+३.०१%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१४.९० करोड
१६.६० करोड
१५.०८ करोड
१५.१० करोड
Cost of goods sold
४.८७ करोड
५.२९ करोड
४.४७ करोड
३.८५ करोड
Cost of revenue
४.८७ करोड
५.२९ करोड
४.४७ करोड
३.८५ करोड
Research and development expenses
५.७२ करोड
५.५८ करोड
५.६८ करोड
५.६८ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७.४७ करोड
७.३० करोड
६.६४ करोड
७.८७ करोड
Operating expense
१३.१८ करोड
१२.८८ करोड
१२.३२ करोड
१३.५५ करोड
Total operating expenses
१८.०५ करोड
१८.१७ करोड
१६.७९ करोड
१७.४० करोड
Operating income
-३.१५ करोड
-१.५६ करोड
-१.७० करोड
-२.३० करोड
Other non operating income
५.३८ लाख
-३०.४४ लाख
-७२.०० हजार
-३४.८७ लाख
EBT including unusual items
-२.८२ करोड
-१.५२ करोड
-१.२८ करोड
-१.८६ करोड
EBT excluding unusual items
-२.६४ करोड
-१.२४ करोड
-१.२९ करोड
-२.२० करोड
Income tax expense
-७.३३ लाख
१०.५९ लाख
६.२३ लाख
-७.१४ लाख
Effective tax rate
२.६०%
-६.९७%
-४.८५%
३.८३%
Other operating expenses
-
-
-
-
Net income
-२.७५ करोड
-१.६३ करोड
-१.३५ करोड
-१.७९ करोड
Net profit margin
-१८.४४%
-९.७९%
-८.९३%
-११.८७%
Earnings per share
-०.०२
०.०७
०.०७
०.०३
Interest and investment income
५१.९९ लाख
६८.९२ लाख
५०.१४ लाख
४७.९७ लाख
Interest expense
-
-
-
-
Net interest expenses
५१.९९ लाख
६८.९२ लाख
५०.१४ लाख
४७.९७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.१२ करोड
-५५.७६ लाख
-७०.८९ लाख
-१.३३ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू